Advertisement

Turner Syndrome: Primary Amenorrhea from Adolescence to Aging

  • Camil Castelo-BrancoEmail author
  • Iuliia Naumova
Chapter

Abstract

Turner syndrome (TS) is a genetic condition occurring in females characterized by partial or complete loss of the second X chromosome resulting in a collection of clinical findings being short stature and primary ovarian insufficiency the hallmarks. However, TS may also involve other complaints including lymphedema, autoimmune diseases, metabolic diseases, cardiac, kidney and bone anomalies, hearing loss, and neurocognitive difficulties which lead to psychosocial and educational inadaptation. Optimizing health care is crucial to allow these individuals succeed in their full potential. This article will provide a review of the current best practice management recommendations for individuals with TS in regard to diagnosis, treatment of short stature, and estrogen supplementation, addressing psychosocial issues, as well screening for other comorbidities. Early identification of TS permits the appropriate screening assessments and well-timed treatment intervention. A multidisciplinary approach with a well-organized transition to adult follow-up health care is required to improve care delivery for this population.

Keywords

Turner syndrome Guidelines Screening Amenorrhea Estrogen therapy Growth failure Growth hormone Infertility Premature ovarian failure Short stature 

References

  1. 1.
    Ros C, Serra A, Balasch J, Margarit E, Castelo-Branco C. Comparative cytogenetic analysis in two tissues with different lineage in Turner’s syndrome patients: correlation with phenotype. Gynecol Endocrinol. 2014;30(4):282–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Bondy CA, Turner T, Consensus S, et al. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. 2014;92:10–25.CrossRefGoogle Scholar
  3. 3.
    Saikia UK, Sarma D, Yadav Y. Delayed presentation of Turner syndrome: challenge to optimal management. J Hum Reprod Sci. 2017;10(4):297–301.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Davenport M. Approach to the patient with Turner syndrome. J Clin Endocrinol Metab. 2010;95:1487–95.PubMedCrossRefGoogle Scholar
  5. 5.
    Marin A, Weir-McCall JR, Webb DJ, et al. Imaging of cardiovascular risk in patients with Turner’s syndrome. Clin Radiol. 2015;70:803–14.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Mortensen KH, Gopalan D, Andersen NH, et al. Multimodality cardiac imaging in Turner syndrome. Cardiol Young. 2016;26:831–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Castelo-Branco C. Management of Turner syndrome in adult life and beyond. Maturitas. 2014;79(4):471–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Donalson MDC, Gault EJ, Tan KW, Dunger DB. Optimising management in Turner syndrome: from infancy to adult transfer. Arch Dis Child. 2006;91:513–20.CrossRefGoogle Scholar
  9. 9.
    Devernay M, Ecosse E, Coste J, Carel JC. Determinants of medical care for young women with Turner Syndrome. J Clin Endocrinol Metab. 2009;94:3408–13.PubMedCrossRefGoogle Scholar
  10. 10.
    Gravholt C. Epidemiological, endocrine and metabolic features in Turner syndrome. Eur J Endocrinol. 2004;151:657–87.PubMedCrossRefGoogle Scholar
  11. 11.
    Elsheikh M, Dunger DB, Conway GS, Wass JAH. Turner’s syndrome in adulthood. Endocr Rev. 2003;23:120–40.Google Scholar
  12. 12.
    Conway GS. The impact and management of Turner’s syndrome in adult life. Best Pract Res Clin Endocrinol Metab. 2002;16:243–61.PubMedCrossRefGoogle Scholar
  13. 13.
    Stockholm K, Juul S, Juel K, Naeraa RW, Gravholt CH. Prevalence, incidence, diagnostic delay and mortality in Turner syndrome. J Clin Endocrinol Metab. 2006;91:3897–902.CrossRefGoogle Scholar
  14. 14.
    Apperley L, Das U, Ramakrishnan R, Dharmaraj P, Blair J, Didi M, Senniappan S. Mode of clinical presentation and delayed diagnosis of Turner syndrome: a single Centre UK study. Int J Pediatr Endocrinol. 2018;2018:4.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Gravholt CH, Andersen NH, Conway GS, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017;177:1–70.CrossRefGoogle Scholar
  16. 16.
    Ros C, Castelo-Branco C. Management of Turner’s syndrome in adult life: case-series and systematic review. Gynecol Endocrinol. 2012;28(9):726–32.PubMedCrossRefGoogle Scholar
  17. 17.
    Bianco SDC, Kaiser UB. The genetic and molecular basis of idiophatic hypogonadotropic hypogonadism. Nat Rev Endocrinol. 2009;5:569–76.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Shankar RK, Backeljauw PF. Current best practice in the management of Turner syndrome. Ther Adv Endocrinol Metab. 2018;9(1):33–40.PubMedCrossRefGoogle Scholar
  19. 19.
    Oliveira CS, Alves C. The role of the SHOX gene in the pathophysiology of Turner syndrome. Endocrinol Nutr. 2011;58:433–42.PubMedCrossRefGoogle Scholar
  20. 20.
    Quigley CA, Crowe BJ, Anglin DG, et al. Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab. 2002;87:2033–41.PubMedCrossRefGoogle Scholar
  21. 21.
    Baxter L, Bryant J, Cave CB, et al. Recombinant growth hormone for children and adolescents with Turner syndrome. Cochrane Database Syst Rev. 2007;(1):CD003887.Google Scholar
  22. 22.
    Ross JL, Quigley CA, Cao D, et al. Growth hormone plus childhood low-dose estrogen in Turner’s syndrome. N Engl J Med. 2011;364:1230–42.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, et al. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab. 2003;88:1119–25.PubMedCrossRefGoogle Scholar
  24. 24.
    Davenport ML, Crowe BJ, Travers SH, et al. Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multi-center trial. J Clin Endocrinol Metab. 2007;92:3406–16.PubMedCrossRefGoogle Scholar
  25. 25.
    Stephure DK, Canadian Growth Hormone Advisory Committee. Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab. 2005;90:3360–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Bell J, Parker KL, Swinford RD, et al. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95:167–77.PubMedCrossRefGoogle Scholar
  27. 27.
    Darendeliler F, Karagiannis G, Wilton P. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm Res. 2007;68(Suppl.5):41–7.PubMedGoogle Scholar
  28. 28.
    Wooten N, Bakalov VK, Hill S, et al. Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab. 2008;93:2109–14.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet. 2000;355:610–3.PubMedCrossRefGoogle Scholar
  30. 30.
    Sas TC, Gault EJ, Bardsley MZ, et al. Safety and efficacy of oxandrolone in growth hormone-treated girls with Turner syndrome: evidence from recent studies and recommendations for use. Horm Res Paediatr. 2014;81:289–97.PubMedCrossRefGoogle Scholar
  31. 31.
    Menke LA, Sas TC, de Muinck Keizer-Schrama SM, et al. Efficacy and safety of oxandrolone in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab. 2010;95:1151–60.PubMedCrossRefGoogle Scholar
  32. 32.
    Pasquino AM, Passeri F, Pucarelli I, et al. Spontaneous pubertal development in Turner’s syndrome. Italian Study Group for Turner’s Syndrome. J Clin Endocrinol Metab. 1997;82:1810–3.PubMedGoogle Scholar
  33. 33.
    Bannink EM, van Sassen C, van Buurent S, de Jong FH, Lequin M, Mulder PGH. Puberty induction in Turner syndrome: results of oestrogen treatment on development of secondary sexual characteristics, uterine dimensions and serum hormone levels. Clin Endocrinol (Oxf). 2009;70:265–73.CrossRefGoogle Scholar
  34. 34.
    Lunding SA, Aksglaede L, Anderson RA, et al. AMH as predictor of premature ovarian insufficiency: a longitudinal study of 120 Turner Syndrome patients. J Clin Endocrinol Metab. 2015;100:1030–8.CrossRefGoogle Scholar
  35. 35.
    Castelo-Branco C, León M, Durán M, Balasch J. Follicle-stimulating hormones does not directly regulate bone mass in human beings: evidence from nature. Fertil Steril. 2008;90:2211–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Ross J, Roentgen D, Zinn A. Cognition and the sex chromosomes: studies in Turner syndrome. Horm Res. 2006;65:47–56.PubMedGoogle Scholar
  37. 37.
    Lim HH, Kil HR, Koo SH. Incidence, puberty, and fertility in 45,X/47,XXX mosaicism: report of a patient and a literature review. Am J Med Genet A. 2018;176(4):1029.Google Scholar
  38. 38.
    Doerr HG, Bettendorf M, Hauffa BP, Mehls O, Partsch CJ. Uterine size in women with Turner syndrome after induction of puberty with estrogens and long-term growth hormone therapy: results of the German IGLU Follow-up Study 2001. Hum Reprod. 2005;5:1418–21.CrossRefGoogle Scholar
  39. 39.
    Foudila T, Soderstrom-Anttila V, Hovatta O. Turner’s syndrome and pregnancies after oocyte donation. Hum Reprod. 1999;14:532–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Breuil V, Euler-Ziegler L. Gonadal dysgenesis and bone metabolism. Joint Bone Spine. 2001;68:26–33.PubMedCrossRefGoogle Scholar
  41. 41.
    Bakalov V, Bondy CA. Fracture risk and bone mineral density in Turner syndrome. Rev Endocr Metab Disord. 2008;9:145–51.PubMedCrossRefGoogle Scholar
  42. 42.
    Sass TC, De Muinck SM, Stijnen T, Asarfi A, Van Leeuwen WJ, Van Teunenbroek A, Van Rijn RR, Drop SL. A longitudinal study on bone mineral density until adulthood in girls with Turner’s syndrome participating in growth hormone injection frequency-response trial. Clin Endocrinol (Oxf). 2000;52:531–6.CrossRefGoogle Scholar
  43. 43.
    Schoemaker MJ, Swerdlow AJ, Higgins CD, et al. Mortality in women with Turner syndrome in Great Britain: a national cohort study. J Clin Endocrinol Metab. 2008;93:4735–42.PubMedCrossRefGoogle Scholar
  44. 44.
    Bondy CA. Heart disease in Turner syndrome. Minerva Endocrinol. 2007;32:245–61.PubMedGoogle Scholar
  45. 45.
    Mortensen KH, Andersen NH, Gravholt CH. Cardiovascular phenotype in Turner syndrome-integrating cardiology, genetics and endocrinology. Endocr Rev. 2012;33:677–714.PubMedCrossRefGoogle Scholar
  46. 46.
    Donato B, Ferreira MJ. Cardiovascular risk in Turner syndrome. Rev Port Cardiol. 2018;37(7):607–21.PubMedCrossRefGoogle Scholar
  47. 47.
    Thomas J, Yetman AT. Management of cardiovascular disease in Turner syndrome. Expert Rev Cardiovasc Ther. 2009;7:1631–41.PubMedCrossRefGoogle Scholar
  48. 48.
    Ross MT, Grafham DV, Coffey AJ, Scherer S, McLay K, Muzny D, et al. The DNA sequence of the human X chromosome. Nature. 2005;434:325–37.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    O’Gorman CS, Syme C, Lang J, Bradley TJ, et al. An evaluation of early cardiometabolic risk factors in children and adolescents with Turner syndrome. Clin Endocrinol (Oxf). 2013;78:907–13.CrossRefGoogle Scholar
  50. 50.
    Akyrek N, Atabek ME, Eklioglu BS, et al. The relationship of periaortic fat thickness and cardiovascular risk factors in children with Turner syndrome. Pediatr Cardiol. 2015;36:925–9.CrossRefGoogle Scholar
  51. 51.
    Berdahl LD, Wenstrom KD, Hanson JW. Web neck anomaly and its association with congenital heart disease. Am J Med Genet. 1995;56:304–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Gravholt CH, Landin-Wilhelmsen K, Stochholm K, et al. Clinical and epidemiological description of aortic dissection in Turner’s syndrome. Cardiol Young. 2006;16:430–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Conway GS, Band M, Doyle J, Davies MC. How do you monitor the patient with Turner’s syndrome in adulthood? Clin Endocrinol (Oxf). 2010;73:696–9.CrossRefGoogle Scholar
  54. 54.
    Sybert VP, McCauley E. Turner’s syndrome. N Engl J Med. 2004;351:1227–38.PubMedCrossRefGoogle Scholar
  55. 55.
    Hong D, Scaletta KJ, Kesler S. Cognitive profile of Turner syndrome. Dev Disabil Res Rev. 2009;15:270–8.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Green T, Bade SS, Chromik LC, et al. Elucidating X chromosome influences on attention deficit hyperactivity disorder and executive function. J Psychiatr Res. 2015;68:217–25.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Mazzocco MM. The cognitive phenotype of Turner syndrome: specific learning disabilities. Int Congr Ser. 2006;1298:83–92.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Nijhuis-van der Sanden MW, Eling PA, Otten BJ. A review of neuropsychological and motor studies in Turner Syndrome. Neurosci Biobehav Rev. 2003;27:329–38.PubMedCrossRefGoogle Scholar
  59. 59.
    McCauley E, Feuillan P, Kushner H, et al. Psychosocial development in adolescents with Turner syndrome. J Dev Behav Pediatr. 2001;22:360–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Sheaffer AT, Lange E, Bondy CA. Sexual function in women with Turner syndrome. J Womens Health (Larchmt). 2008;17(1):27–33.CrossRefGoogle Scholar
  61. 61.
    Cardoso G, Daly R, Haq NA, et al. Current and lifetime psychiatric illness in women with Turner syndrome. Gynecol Endocrinol. 2004;19(6):313–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Garrido Oyarzun MF, Castelo-Branco C. Sexuality and quality of life in congenital hypogonadism. Gynecol Endocrinol. 2016;32(12):947–50.PubMedCrossRefGoogle Scholar
  63. 63.
    Ros C, Alobid I, Balasch J, et al. Turner’s syndrome and other forms of congenital hypogonadism impair quality of life and sexual function. Am J Obstet Gynecol. 2013;208(6):484–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Carel JC, Elie C, Ecosse E, et al. Self-esteem and social adjustment in young women with Turner syndrome—influence of pubertal management and sexuality: population-based cohort study. J Clin Endocrinol Metab. 2006;91(8):2972–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Chadwick PM, Smyth A, Liao LM. Improving self-esteem in women diagnosed with Turner syndrome: results of a pilot intervention. J Pediatr Adolesc Gynecol. 2014;27:129–32.PubMedCrossRefGoogle Scholar
  66. 66.
    Heilbronner RL, Sweet JJ, Attix DK, et al. Official position of the American Academy of Clinical Neuropsychology on serial neuropsychological assessments: the utility and challenges of repeat test administrations in clinical and forensic contexts. Clin Neuropsychol. 2010;24:1267–78.PubMedCrossRefGoogle Scholar
  67. 67.
    Ros C, Tercero A, Alobid I, Balasch J, Santamaria J, Mullol J, Castelo-Branco C. Hearing loss in adult women with Turner's syndrome and other congenital hypogonadisms. Gynecol Endocrinol. 2014;30(2):111–6.PubMedCrossRefGoogle Scholar
  68. 68.
    Verver EJ, Freriks K, Thomeer HG, Huygen PL, Pennings RJ, Alfen-van der Velden AA, Timmers HJ, Otten BJ, Cremers CW, Kunst HP. Ear and hearing problems in relation to karyotype in children with Turner syndrome. Hear Res. 2011;275(1–2):81–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Kubba H, Smyth A, Wong SC, Mason A. Ear health and hearing surveillance in girls and women with Turner’s syndrome: recommendations from the Turner’s Syndrome Support Society. Clin Otolaryngol. 2017;42(3):503–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Hederstierna C, Hultcrantz M, Rosenhall U. A longitudinal study of hearing decline in women with Turner syndrome. Acta Otolaryngol. 2009;129:1434–41.PubMedCrossRefGoogle Scholar
  71. 71.
    Bergamaschi R, Bergonzoni C, Mazzanti L, Scarano E, Mencarelli F, Messina F, Rosano M, Iughetti L, Cicognani A. Hearing loss in Turner syndrome: results of a multicentric study. J Endocrinol Invest. 2008;31(9):779–83.PubMedCrossRefGoogle Scholar
  72. 72.
    Hall JE, Richter GT, Choo DI. Surgical management of otologic disease in pediatric patients with Turner syndrome. Int J Pediatr Otorhinolaryngol. 2009;73(1):57–65.PubMedCrossRefGoogle Scholar
  73. 73.
    Hederstierna C, Hultcrantz M, Rosenhall U. Estrogen and hearing from a clinical point of view; characteristics of auditory function in women with Turner syndrome. Hear Res. 2009;252:3–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Parkin M, Walker P. Hearing loss in Turner syndrome. Int J Pediatr Otorhinolaryngol. 2009;73:243–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Mortensen KH, Cleemann L, Hjerrild BE, et al. Increased prevalence of autoimmunity in Turner syndrome—influence of age. Clin Exp Immunol. 2009;156:205–10.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Grossi A, Crino A, Luciano R, Lombardo A, Cappa M, Fierabracci A. Endocrine autoimmunity in Turner syndrome. Ital J Pediatr. 2013;39:79.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Gravholt CH. Clinical practice in Turner syndrome. Nat Clin Pract Endocrinol Metab. 2005;1:41–52.PubMedCrossRefGoogle Scholar
  78. 78.
    Bronshtein M, Zimmer EZ, Blazer S. A characteristic cluster of fetal sonographic markers that are predictive of fetal Turner syndrome in early pregnancy. Am J Obstet Gynecol. 2003;188:1016–20.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Faculty of Medicine, Institut Clinic of Gynecology, Obstetrics and NeonatologyUniversity of Barcelona, Hospital Clinic-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)BarcelonaSpain
  2. 2.Department of Obstetrics and Gynecology, Faculty of General MedicineSaratov State Medical University n.a. V.I. RazumovskySaratovRussia

Personalised recommendations